1. A protector structure for an electric power feeding apparatus comprising a curved wall portion provided at one wall of an upwardly extending guiding cylinder of a protector, the curved wall portion continuing to a top opening of the guiding cylinder such that a wiring harness is bendably pulled out along the curved wall portion, and the curved wall portion having a first side opening for exiting of a foreign matter, the first side opening being proximate to the opening.
2. A protector structure for an electric power feeding apparatus comprising:
a curved wall portion provided at one side wall of an upwardly extending guiding cylinder of a protector having a first side opening, the curved wall portion continuing to a top opening of the guiding cylinder such that a wiring harness is bendably pulled out along the curved wall portion;
an other side wall of the guiding cylinder; and
a second side opening for exiting of a foreign matter provided on the other side wall of the guiding cylinder, the second side opening being proximate to the top opening and the other side wall being opposite the curved wall portion of the guiding cylinder.
3. The protector structure for the electric power feeding apparatus according to claim 2, further comprising a projection provided inside of the guiding cylinder and on the other side wall thereof, the projection projecting from a lower side of the side opening and having an upwardly sloping surface continuing to the side opening.
4. The protector structure for the electric power feeding apparatus according to claim 2, further comprising a projection provided inside of the guiding cylinder and on the other side wall thereof, the projection projecting from an upper side of the side opening and traversing inside of the guiding cylinder.
5. The protector structure for the electric power feeding apparatus according to claim 4, wherein the protector includes two separate protector members, the one separate protector member having the projection that extends towards the other separate protector member such that a joining area between the separate protector members is covered by the projection.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the formula I:
or a pharmaceutically acceptable salt or solvate of said compound, wherein:
L1 is a covalent bond, \u2014CH2\u2014, \u2014C(O)\u2014, \u2014C(O)O\u2014, \u2014S(O2)\u2014, \u2014S(O)\u2014, \u2014S\u2014, \u2014O\u2014, \u2014NH\u2014, or
L2 is \u2014CH2\u2014, \u2014C(H)(alkyl)-, \u2014C(alkyl)2\u2014, \u2014C(O)\u2014, \u2014SO\u2014, \u2014S(O2,)\u2014, \u2014C(\u2550NR7)\u2014, \u2014C(\u2550N\u2014CN)\u2014 or \u2014C(\u2550N\u2014OR7);
L3 is a covalent bond, \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is selected from the group consisting of H, halogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, \u2014NHR7, \u2014N(R7)2, \u2014C(O)R7, \u2014C(O)OR7, \u2014S(O2) R7, \u2014Si(alkyl)n(aryl)3-n, aryl and heteroaryl, wherein each of said aryl or heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy, \u2014N(R7)2, \u2014C(O)OR7, \u2014C(O)N(R7)2, \u2014NC(O)R7, \u2014NC(O)OR7, \u2014NC(O)N(R7)2, \u2014NO2, \u2014CN, \u2014S(O2)R7, \u2014S(O2)N(R7)2, \u2014NC(\u2550N\u2014CN)NHR7, and OH, with the proviso that:
e) when R1 is halogen, L1 is a covalent bond;
f) when R1 is \u2014NHR7 or \u2014N(R7)2, L1 is a covalent bond, \u2014CH2\u2014, \u2014C(O)\u2014, \u2014S(O2)\u2014 or \u2014SO\u2014;
g) when R1 is \u2014C(O)R7 or \u2014C(O)OR7, L1 is a covalent bond, \u2014CH2\u2014, \u2014NH\u2014 or \u2014N(alkyl)-; and
h) when R1 is \u2014S(O2)R7 or \u2014C(O)OR7, L1 is a covalent bond, \u2014CH2\u2014, \u2014NH\u2014 or \u2014N(alkyl)-;
R2 is H, \u2014OH, halogen, \u2014N(R7)2\u2014, \u2014CF3, alkoxy, alkyl, haloalkyl, cycloalkyl or cycloalkylalkyl;
R3 and R4 are the same or different, and are independently H or alkyl, or R3 and R4 taken together form a carbonyl group, i.e. C(\u2550O);
R5 is H or alkyl;
R6 is selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl, NHR7, N(R7)2, aryl and heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which moieties can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, alkoxy and OH;
R7 is selected from H, alkyl, haloalkyl, cycloalkyl, heterocyclylalkyl, aryl and heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which moieties can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, alkoxy andor OH;
A is selected from phenyl, naphthyl, pyridyl, thienyl, thiazolyl, quinolyl, isoquinolyl, pyrazinyl, pyridazinyl, furanyl, pyrrolyl, pyrimidyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, benzofuranyl, and benzothienyl;
X is independently selected from the group consisting of H, halogen, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, alkoxycarbonyl, haloalkoxy, \u2014N(R7)2, \u2014N(R7)(C(O)R7), \u2014N(R7)(C(O)OR7), \u2014NO2 and \u2014CN, and when A is selected from the group consisting of pyridyl, thienyl, thiazolyl, quinolyl, isoquinolyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrimidyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, and benzothienyl, X can be oxide; and
n is 0-3,
with the proviso that (i) the two R7 moieties in \u2014N(R7)2 can be the same or different and are independently selected, and (ii) the moiety \u2014N(R5)-L3-R6 can optionally form a ring system.
2. A compound according to claim 1 wherein
L1 is \u2014CH2\u2014, \u2014C(O)\u2014, \u2014S(O)\u2014, \u2014C(O)O\u2014, or \u2014S(O2)\u2014;
L2 is \u2014CH2\u2014, \u2014CH(alkyl), \u2014C(alkyl)2\u2014, \u2014C(O)\u2014, \u2014SO\u2014 or \u2014S(O2)\u2014;
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, \u2014N(R7)2, \u2014CN, (C1-C6)alkoxy and OH;
R2 is H, OH, halogen, CF3, alkoxy, \u2014N(R7)2, (C1-C6)alkyl, (C1-C6)haloalkyl, \u2014CH2\u2014(C3-C5)cycloalkyl, or (C3-C5)cycloalkyl;
R3 and R4 are the same or different, and are independently selected from H or (C1-C6)alkyl;
R5 is H or (C1-C6)alkyl;
R6 is H, (C1-C6)alkyl, or haloalkyl;
A is phenyl, naphthyl, furanyl or pyridyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl, hydroxy, alkoxy, and haloalkoxy and
n is 0-2.
3. A compound according to claim 1 wherein
L1 is \u2014CH2\u2014, \u2014C(O)O\u2014 or \u2014S(O2)\u2014;
L2 is \u2014CH2\u2014 or \u2014S(O2)\u2014;
L 3 is \u2014C(O)\u2014 or S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, (C1-C6)alkoxy and OH;
R2 is H, OH, halogen, CF3, alkoxy, (C1-C6)alkyl, (C1-C6)haloalkyl, \u2014CH2\u2014(C3-C5)cycloalkyl or (C3-C5)cycloalkyl;
R3 and R4 are H;
R5 is H or C1-C6 alkyl;
R6 is H, C1-C6 alkyl, or haloalkyl;
A is phenyl or pyridyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl, hydroxy, alkoxy, and haloalkoxy and
n is 0-2.
4. The compound according to claim 1 having the formula 2:
wherein:
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, (C1-C6)alkoxy and OH;
R2 is H, OH, F, (C1-C6)alkyl, (C1-C6)haloalkyl, alkoxy or (C3-C5)cycloalkyl;
R6 is H, C1-C6 alkyl, or haloalkyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl alkoxy, hydroxy and haloalkoxy and
n is 0-2.
5. The compound according to claim 1 having the formula 3:
wherein:
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, (C1-C6)alkoxy and OH;
R2 is H, OH, F, (C1-C6)alkyl, (C1-C6)haloalkyl, alkoxy or (C3-C5)cycloalkyl;
R6 is H, C1-C6 alkyl, or haloalkyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl, alkoxy, hydroxy and haloalkoxy and
n is 0-2.
6. The compound according to claim 1 wherein:
L1 is \u2014C(O)O\u2014 or \u2014S(O2)\u2014;
L2 is \u2014S(O2)\u2014;
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is selected from the group consisting of t-butyl, i-propyl, neopentyl, 2-trifluoromethyl-2-propyl, 1,1-bis(trifluoromethyl)-1-ethyl, 2-fluorophenyl, 2,6-difluorophenyl, 2-pyridyl, and 2-pyrimidyl;
R2 is H, F, (C1-C6)alkyl, OH, or alkoxy;
R3\u2550R4\u2550H;
R5 is H;
R6 is CH3 or CF3;
A is phenyl, indolyl or pyridyl;
X is selected from the group consisting of H, F, Cl, Br, CF3, \u2014OCH3, \u2014OCF3 and \u2014OCHF2; and
n is 0-2.
7. The compound according to claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A, L1, L2, L3 and X are as set forth in the following table:
Cmp
R1
R2
R3
R4
R6
A =
L1
L2
L3
X
A
H
H
H
CF3
CO2
SO2
SO2
Cl
B
H
H
H
CH3
CO2
SO2
SO2
OCF3
C
H
H
H
CF3
CO2
SO2
SO2
Cl
D
H
H
H
CF3
CO2
SO2
SO2
H
E
H
H
H
CF3
CO2
SO2
SO2
Cl
F
H
H
H
CH3
CO2
SO2
SO2
Cl
G
H
H
H
CF3
CO2
SO2
SO2
Cl
H
i-propyl
H
H
H
CF3
CO2
SO2
SO2
Cl
I
H
H
H
CH3
CO2
SO2
SO2
H
J
H
H
H
CH3
SO2
SO2
SO2
OCH3
K
H
H
H
CH3
SO2
SO2
SO2
OCH3
L
H
H
H
CH3
SO2
SO2
SO2
OCF2H
M
H
H
H
CH3
SO2
SO2
SO2
OCF3
N
H
H
H
C2H5
SO2
SO2
SO2
OCF2H
O
H
H
H
CH3
SO2
SO2
SO2
Cl
P
H
H
H
C2H5
SO2
SO2
SO2
OCF3
Q
H
H
H
CF3
SO2
SO2
SO2
CF3
R
H
H
H
CF3
SO2
SO2
SO2
Cl
S
H
H
H
CF3
SO2
SO2
C\u2550O
OCH3
T
H
H
H
CH3
SO2
SO2
SO2
H
U
H
H
H
CF3
SO2
SO2
C\u2550O
OCH3
V
Br
H
H
H
CH3
CB
SO2
SO2
H
W
H
H
H
CH3
CB
SO2
SO2
H
X
C3H7
H
H
H
CH3
SO2
SO2
SO2
OCH3
Y
H
H
H
CF3
SO
SO2
C\u2550O
Cl
Z
H
H
H
CF3
SO2
CH2
C\u2550O
Cl
AA
H
H
H
CF3
S
CH2
C\u2550O
Cl
AB
H
H
H
CH3
CH2
SO2
SO2
Cl
AC
H
H
H
CH3
CH2
SO2
SO2
Cl
AD
H
H
H
CH3
C\u2550O
SO2
SO2
Cl
AE
H
H
H
H
CF3
CB
SO2
SO2
H
AF
H
H
H
H
CH3
CB
SO2
SO2
H
AG
H
H
H
CH3
SO2
SO2
SO2
H
AH
Si(CH3)3
H
H
H
CH3
CB
SO2
SO2
Cl
Al
Br
H
H
H
CH3
CB
SO2
SO2
H
AJ
H
H
H
CH3
NH
SO2
SO2
H
AK
OCH3
H
H
CH3
CO2
SO2
SO2
Cl
AL
CH3
H
H
CF3
SO2
SO2
SO2
Cl
AM
CH3
H
H
CH3
SO2
SO2
SO2
Cl
AN
CH3
H
H
CF3
CO2
SO2
SO2
Cl
AP
H
H
H
CF3
CO2
SO2
SO2
OCH3
AQ
F
H
H
CF3
SO2
SO2
SO2
Cl
AR
F
H
H
CF3
CO2
SO2
SO2
Cl
AS
F
H
H
CF3
SO2
SO2
SO2
Cl
AU
F
H
H
CF3
SO2
SO2
SO2
Cl
AV
OCH3
H
H
CF3
SO2
SO2
SO2
Cl
AW
OCH3
H
H
CF3
SO2
SO2
SO2
Cl
AX
OCH3
H
H
CF3
CO2
SO2
SO2
Cl
AY
H
H
H
CH3
SO2
SO2
SO2
OCF3
AZ
H
H
H
CF3
SO2
SO2
SO2
OCF3
BA
H
H
H
CF3
SO2
SO2
SO2
Cl
BD
H
H
H
CF3
CO2
SO2
SO2
OCF3
BE
H
H
H
CF3
CO2
SO2
SO2
Cl
BF
H
CH3
CH3
CF3
SO2
SO2
SO2
Cl
BG
H
CH3
CH3
CF3
SO2
SO2
C\u2550O
CF3
BH
H
CH3
CH3
CF3
SO2
SO2
C\u2550O
Cl
BI
H
CH3
CH3
CF3
SO2
SO2
SO2
CF3
BJ
H
CH3
CH3
H
SO2
SO2
CB
CF3
BK
H
CH3
CH3
CF3
CO2
SO2
SO2
Cl
BL
F
H
H
CF3
SO2
SO2
SO2
CF3
BM
OCH3
H
H
CF3
S
SO2
SO2
Cl
BN
F
H
H
CF3
CO2
SO2
SO2
CF3
BO
F
H
H
CF3
SO2
SO2
SO2
Cl
BP
OH
H
H
CF3
CO2
SO2
SO2
Cl
BQ
H
H
CH3
CO2
SO2
SO2
Cl
BR
F
H
H
CF3
SO2
SO2
SO2
Cl
BS
H
H
CH3
CO2
SO2
SO2
Cl
BT
CH3
H
H
CF3
SO2
SO2
C\u2550O
Cl
BU
H
H
CF3
CO2
SO2
SO2
Cl
BV
OH
H
H
CH3
CO2
SO2
SO2
Cl
BW
F
H
H
CF3
SO2
SO2
C\u2550O
Cl
BX
C3H7
H
H
CF3
CO2
SO2
SO2
Cl
BY
F
H
H
CF3
SO2
SO2
SO2
Cl
BZ
H
H
CF3
CO2
SO2
SO2
Cl
CA
H
H
H
CF3
SO2
SO2
C\u2550O
Cl
CB
H
H
H
CF3
SO2
SO2
SO2
H
CC
H
H
H
CF3
SO2
SO2
SO2
Cl
CD
H
H
H
CF3
SO2
SO2
C\u2550O
Cl
CE
H
H
H
CF3
SO2
SO2
C\u2550O
OCF2H
CF
H
H
H
CH3
SO2
SO2
SO2
H
CG
H
H
H
CF3
SO2
SO2
C\u2550O
H
CH
H
H
H
CF3
SO2
SO2
C\u2550O
OCH3
CI
H
H
H
C2H5
SO2
SO2
SO2
OCF3
CJ
H
H
H
CH3
SO2
SO2
SO2
OCF3
CK
H
H
H
CF3
SO2
SO2
SO2
OCF3
CL
H
H
H
CF3
SO2
SO2
C\u2550O
OCF3
CM
H
H
H
CF3
SO2
SO2
C\u2550O
CF3
CN
H
H
H
CF3
SO2
SO2
C\u2550O
OCF3
CO
H
H
H
CH3
SO2
SO2
SO2
Cl
CP
C4H9
H
H
H
CH3
SO2
SO2
SO2
Cl
CQ
H
H
H
C2H5
CO2
SO2
SO2
Cl
CR
CH3
H
H
H
CF3
CO2
SO2
C\u2550O
H
CS
H
H
H
CF3
CO2
SO2
SO2
CF3
CT
H
H
H
CF3
CB
SO2
C\u2550O
H
CU
H
H
H
CH3
CB
SO2
SO2
H
CV
Cl
H
H
H
CH3
CB
SO2
SO2
Br
CW
H
H
H
CH3
CB
SO2
SO2
H
CX
F
H
H
CF3
CO2
SO2
C\u2550O
Cl
CY
H
H
H
H
CH3
CB
SO2
SO2
H
DA
F
H
H
CF3
SO
SO2
SO2
Cl
DB
F
H
H
CF3
SO
SO2
SO2
Cl
DC
H
H
H
CF3
SO2
CH2
C\u2550O
OCF3
DD
CH3
H
O*
O*
H
CO2
SO2
CB
H
DE
H
H
H
CH3
CB
SO2
SO2
H
DF
H
H
H
CH3
CB
SO2
SO2
H
DG
H
H
H
N(CH3)2
CO2
SO2
SO2
Cl
DH
Br
H
H
H
CH3
CB
SO2
SO2
H
DI
CH3
H
H
H
CH3
CB
SO2
SO2
t-butyl
DK
OCH3
H
H
CF3
SO2
SO2
SO2
Cl
DL
OC2H5
H
H
H
S
SO2
CB
Cl
DM
OCH3
H
H
CH3
SO2
SO2
SO2
Cl
DN
F
H
H
CF3
SO
SO2
SO2
Cl
DO
OC2H5
H
H
CF3
SO2
SO2
SO2
Cl
DP
OCH3
H
H
CH3
SO2
SO2
SO2
Cl
DQ
F
H
H
CF3
SO2
SO2
SO2
Cl
DR
F
H
H
CF3
SO2
SO2
SO2
Cl
DS
F
H
H
CF3
SO2
SO2
SO2
Cl
DT
CH3
H
H
H
CH3
SO2
SO2
SO2
Cl
CB = covalent bond
*R3 and R4 taken together form a carbonyl group (C\u2550O).
8. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R6, A, L1, and X are as set forth in the following table:
Cmp.
R1
R2
R6
A
L1
X
A
H
CF3
CO2
Cl
C
H
CF3
CO2
Cl
D
H
CF3
CO2
H
E
H
CF3
CO2
Cl
F
H
CH3
CO2
Cl
G
H
CF3
CO2
Cl
H
i-propyl
H
CF3
CO2
Cl
J
H
CH3
SO2
OCH3
L
H
CH3
SO2
OCF2H
M
H
CH3
SO2
OCF3
N
H
C2H5
SO2
OCF2H
Q
H
CF3
SO2
CF3
AK
OCH3
CH3
CO2
Cl
AL
CH3
CF3
SO2
Cl
AM
CH3
CH3
SO2
Cl
AN
CH3
CF3
CO2
Cl
AP
H
CF3
CO2
OCH3
AQ
F
CF3
SO2
Cl
AR
F
CF3
CO2
Cl
AS
F
CF3
SO2
Cl
AU
F
CF3
SO2
Cl
AV
OCH3
CF3
SO2
Cl
AW
OCH3
CF3
SO
Cl
AX
OCH3
CF3
CO2
Cl
AZ
H
CF3
SO2
OCF3
BD
H
CF3
CO2
OCF3
BE
H
CF3
CO2
Cl
DK
OCH3
CF3
SO2
Cl
DM
OCH3
CH3
SO2
Cl
DO
OC2H5
CF3
SO2
Cl
DP
OCH3
CH3
SO2
Cl
CB = covalent bond
* R3 and R4 taken together form a carbonyl group (C\u2550O).
9. The compound according to claim 1 having the formula:
10. The compound according to claim 1 having the formula:
11. The compound according to claim 1 having the formula:
12. The compound according to claim 1 having the formula:
13. The compound according to claim 1 having the formula:
14. The compound according to claim 1 having the formula:
15. The compound according to claim 1 having the formula:
16. The compound according to claim 1 having the formula:
17. The compound according to claim 1 having the formula:
18. The compound according to claim 1 having the formula:
19. The compound according to claim 1 having the formula:
20. The compound according to claim 1 having the formula:
21. The compound according to claim 1 having the formula:
22. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising an effective amount of a compound according to claim 9 and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprising an effective amount of a compound according to claim 10 and a pharmaceutically acceptable carrier.
25. A method of treating cancer, inflammatory diseases, immunomodulatory diseases, or respiratory diseases comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 1.
26. A method of treating cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, sepsis, shock, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing aveolitis, psoriasis, transplant rejection, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn’s disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD) or bronchitis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 1.
27. The method of claim 25 wherein the condition or disease treated is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, seasonal allergic rhinitis, psoriasis, transplant rejection and chronic obstructive pulmonary disease.
28. A process for making a pharmaceutical composition comprising combining a compound of claim 1 and a pharmaceutically acceptable carrier.
29. A method of treating rheumatoid arthritis comprising administering to a mammal in need thereof an effective amount of a compound of claim 1 in combination with at least one compound selected from the group consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
30. A method of treating rheumatoid arthritis comprising administering to a mammal in need thereof an effective amount of a compound of claim 10 in combination with at least one compound selected from the group consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
31. The method of claim 29 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine, or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
32. The method of claim 30 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine, or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
33. A composition for treating rheumatoid arthritis which comprises an effective amount of a compound of claim 1 and a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
34. A composition for treating rheumatoid arthritis which comprises an effective amount of a compound of claim 10 and a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
35. The composition of claim 33 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine, or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
36. The composition of claim 34 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
37. A method of treating multiple sclerosis comprising administering to a mammal in need thereof an effective amount of a compound of claim 1 in combination with an effective amount of a compound selected from the group consisting of Avonex, Betaseron and Copaxone.
38. A method of treating multiple sclerosis comprising administering to a mammal in need thereof an effective amount of a compound of claim 10 in combination with an effective amount of a compound selected from the group consisting of Avonex, Betaseron and Copaxone.
39. A composition for treating multiple sclerosis which comprises an effective amount of a compound of claim 1 and a compound selected from Avonex, Betaseron and Copaxone.
40. A composition for treating multiple sclerosis which comprises an effective amount of a compound of claim 10 and a compound selected from the group consisting of Avonex, Betaseron and Copaxone.
41. A method of treating psoriasis comprising administering to a mammal in need thereof an effective amount of a compound as defined in claim 1 in combination with a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
42. A method of treating psoriasis comprising administering to a mammal in need thereof an effective amount of a compound as defined in claim 10 in combination with a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
43. The method of claim 41 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
44. The method of claim 42 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
45. A composition for treating psoriasis which comprises an effective amount of a compound of claim 1 and a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
46. A composition for treating psoriasis which comprises an effective amount of a compound of claim 10 and a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
47. The composition of claim 45 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
48. The composition of claim 46 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
49. A method of treating seasonal allergic rhinitis andor asthma comprising an effective amount of a compound of claim 1 in combination with an H1 antagonist.
50. A composition for treating seasonal allergic rhinitis andor asthma which comprises an effective amount of an H1 antagonist and an effective amount of a compound of claim 1.
51. The composition of claim 50 wherein the H1 antagonist is selected from the group consisting of Claritin, Clarinex, Zyrtec and Allegra.